Target intelligence / Profile preview

WW domain-containing transcription regulator protein 1 (TAZ)

Target
TAZ
Molecular classification
Transcription factor, Other
01

Overview

WW domain-containing transcription regulator protein 1 (WWTR1), commonly known as TAZ (transcriptional coactivator with PDZ-binding motif), is a key downstream effector of the Hippo signaling pathway. TAZ acts as a transcriptional coactivator that shuttles between the cytoplasm and the nucleus, where it binds to TEAD transcription factors to drive the expression of genes involved in cell proliferation, survival, and stem cell self-renewal. Under normal physiological conditions, TAZ is regulated by upstream Hippo pathway kinases (such as MST1/2 and LATS1/2) which phosphorylate TAZ, leading to its cytoplasmic retention and proteasomal degradation. However, in many human cancers, dysregulation of the Hippo pathway or mechanical cues from a stiff extracellular matrix lead to aberrant nuclear accumulation of TAZ, promoting tumor growth, metastasis, epithelial-mesenchymal transition (EMT), and drug resistance.\n\nConsequently, TAZ has emerged as an attractive therapeutic target in oncology, particularly for Hippo-mutant tumors like malignant pleural mesothelioma. Therapeutic strategies include direct disruptors of the YAP/TAZ-TEAD protein-protein interaction (such as IAG933) and small-molecule inhibitors of TEAD palmitoylation (such as VT3989 and IK-930) that indirectly prevent TAZ-mediated transcription. However, systemic inhibition of TAZ poses significant safety challenges, most notably renal toxicity (such as podocyte damage and proteinuria) and impaired tissue regeneration, necessitating carefully designed dosing regimens.

Other names
Transcriptional coactivator with PDZ-binding motifWWTR1TAZTAZ1
02

Mechanism of action

Disruption of the YAP/TAZ-TEAD protein-protein interaction, inhibition of TEAD auto-palmitoylation, and prevention of TAZ nuclear translocation.

03

Biological functions

Signal transductionCell cycleApoptosisCell proliferationCell deathOther
04

Disease associations

CancerInflammationOther
05

Safety considerations

Renal toxicity (podocyte damage, proteinuria, and tubular degeneration)Impaired tissue repair and regenerationHepatotoxicity and liver injuryEmbryonic lethality and developmental defects
06

Interacting drugs

10 more in the full profile.

07

Biomarkers

TAZ expression levelWWTR1 expression levelYAP/TAZ nuclear localizationNF2 mutation statusLATS1/2 mutation statusTEAD target gene expression (e.g., CCN1, CCN2, ANKRD1)

Beyond the preview

Go deeper on WW domain-containing transcription regulator protein 1 (TAZ).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on WW domain-containing transcription regulator protein 1 (TAZ).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call